Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alkermes plc (ALKS)
:ALKS
ALKS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$22.90 - $36.06
Previous CloseN/A
Volume176.14K
Average Volume (3M)1.73M
Market Cap
$5.85B
Enterprise Value$4.13B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)16.5
Beta0.80
Next Earnings
Apr 23, 2025EPS Estimate
0.29Last Dividend Ex-Date
Nov 16, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)2.18
Shares Outstanding162,614,060
10 Day Avg. Volume2,350,054
30 Day Avg. Volume1,731,055
Standard Deviation0.10
R-Squared0.05
Alpha0.00997
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.89
Price to Cash Flow (P/CF)17.90
P/FCF Ratio20.00
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.15
Enterprise Value/Ebitda8.75
Forecast
1Y Price Target
$38.45Price Target Upside7.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAlkermes ended 2024 debt-free with a significant cash reserve of $824.8M, which strengthens its financial position.
Phase 2 TrialsEnrollment for ALKS 2680 Phase 2 trials in narcolepsy is progressing well in the US, EU, and Australia, indicating strong development potential.
Safety ProfileALKS-2680 has a clean safety profile, reducing concerns about liver toxicity.
Bears Say
Earnings GuidanceThe 2025 revenue and EBITDA guidance is below consensus expectations, indicating potential challenges in meeting market predictions.
Investor ConcernsInvestors might view the latest financial results as low quality due to the influence of channel inventory fluctuations.
Sales PerformanceThe 2025 top-line guide is slightly lower than consensus estimates, with lighter than expected sales guidance for Aristada and Lybalvi.
---
Ownership Overview
1.60% Insiders
33.72% Mutual Funds
23.23% Other Institutional Investors
8.42% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALKS FAQ
What was Alkermes plc’s price range in the past 12 months?
Alkermes plc lowest stock price was $22.90 and its highest was $36.06 in the past 12 months.
What is Alkermes plc’s market cap?
Alkermes plc’s market cap is $5.85B.
When is Alkermes plc’s upcoming earnings report date?
Alkermes plc’s upcoming earnings report date is Apr 23, 2025 which is in 66 days.
How were Alkermes plc’s earnings last quarter?
Alkermes plc released its earnings results on Feb 12, 2025. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $0.759 by $0.291.
Is Alkermes plc overvalued?
According to Wall Street analysts Alkermes plc’s price is currently Undervalued.
Does Alkermes plc pay dividends?
Alkermes plc pays a Notavailable dividend of $1.639 which represents an annual dividend yield of N/A. See more information on Alkermes plc dividends here
What is Alkermes plc’s EPS estimate?
Alkermes plc’s EPS estimate is 0.29.
How many shares outstanding does Alkermes plc have?
Alkermes plc has 162,614,060 shares outstanding.
What happened to Alkermes plc’s price movement after its last earnings report?
Alkermes plc reported an EPS of $1.05 in its last earnings report, beating expectations of $0.759. Following the earnings report the stock price went up 4.819%.
Which hedge fund is a major shareholder of Alkermes plc?
Currently, no hedge funds are holding shares in ALKS
---
Alkermes Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.45 (7.13% Upside)
$38.45 (7.13% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 137.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.22%
12-Months-Change
Fundamentals
Return on Equity
27.90%
Trailing 12-Months
Asset Growth
-3.78%
Trailing 12-Months
Company Description
Alkermes plc
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
---
ALKS Company Deck
---
ALKS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance in 2024 with record revenues, significant progress in pipeline development, and strategic debt management. However, challenges such as anticipated reductions in manufacturing and royalty revenues and the need for continued growth in mature product lines present headwinds. The company's strategic focus on profitability and pipeline advancement, particularly with ALKS 2680, positions it well for future growth.Read More>---
ALKS Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
---
ALKS Stock 12 Month Forecast
Average Price Target
$38.45
▲(7.13% Upside)
Technical Analysis
Best Analysts Covering ALKS
1 Year
1 Year Success Rate
11/12 ratings generated profit
1 Year Average Return
+28.34%
reiterated a buy rating 3 days ago
Copying Paul Matteis's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +28.34% per trade.
---